Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Effects of Four-Cell Galvanic Therapy on Pain and Balance in Diabetic Peripheral Neuropathy (GABATH-DPN)

10 de maio de 2026 atualizado por: ALP KAAN SAFA YAŞAR, Ankara Etlik City Hospital

Effects of Four-Cell Galvanic Bath Therapy on Pain and Balance in Patients With Diabetic Distal Symmetric Polyneuropathy: A Prospective, Randomized, Controlled, Single-Blind Study

This study aims to evaluate the effects of four-cell galvanic bath therapy on pain and balance in patients with diabetic distal symmetric polyneuropathy. Diabetic peripheral neuropathy is a common complication of diabetes that can lead to pain, sensory loss, and impaired balance. In this randomized controlled study, participants received either conventional rehabilitation alone or conventional rehabilitation combined with four-cell galvanic bath therapy. The intervention was applied over a 4-week period. Pain and balance outcomes were assessed using standardized clinical measures. The findings of this study may help determine the effectiveness of galvanic bath therapy as a supportive treatment option in patients with diabetic neuropathy.

Visão geral do estudo

Descrição detalhada

Diabetic distal symmetric polyneuropathy (DSPN) is one of the most prevalent chronic complications of diabetes mellitus and is characterized by progressive peripheral nerve damage, leading to symptoms such as distal sensory loss, neuropathic pain, and impaired proprioception. These alterations negatively affect postural control mechanisms, resulting in balance impairment, increased risk of falls, and reduced functional independence. As a consequence, DSPN significantly decreases quality of life and poses an important clinical and socioeconomic burden.

Conventional rehabilitation programs, including range of motion, strengthening, balance, coordination, and endurance exercises, are commonly used in the management of DSPN. However, despite these interventions, persistent neuropathic pain and balance deficits often remain inadequately controlled. Therefore, there is a growing interest in adjunctive therapeutic approaches that target both sensory and motor components of postural control.

Electrical stimulation modalities have been proposed as potential therapeutic options due to their ability to modulate peripheral nerve excitability and enhance somatosensory feedback. Four-cell galvanic bath therapy is a non-invasive intervention that applies low-intensity direct current through water-filled electrodes to the upper and lower extremities. This method may stimulate cutaneous receptors and peripheral nerve endings, increase afferent sensory input, and facilitate neuromuscular activation. Through these mechanisms, galvanic bath therapy may contribute to improved postural stability and reduction of neuropathic pain. However, current evidence regarding its combined effects on both pain and balance in patients with DSPN is limited, highlighting the need for well-designed clinical trials.

This study was designed as a prospective, randomized, controlled, single-blind clinical trial including patients aged 40-75 years diagnosed with DSPN. Participants were randomly assigned in a 1:1 ratio to either an intervention group receiving four-cell galvanic bath therapy in addition to conventional rehabilitation or a control group receiving only conventional rehabilitation. The rehabilitation program consisted of standardized exercises including range of motion, stretching, strengthening, balance, coordination, and endurance training, and was applied for 4 weeks, three sessions per week, with each session lasting approximately one hour.

In the intervention group, four-cell galvanic bath therapy was administered concurrently with the conventional rehabilitation program. The application was performed using a standardized protocol to ensure consistency across participants. Outcome measures were assessed at baseline and after the intervention period using validated clinical assessment tools. Pain intensity and balance performance were evaluated as primary outcomes, while additional functional and quality of life parameters were assessed as secondary outcomes.

The primary objective of this study is to investigate the effectiveness of four-cell galvanic bath therapy on reducing pain and improving balance in patients with DSPN. A secondary objective is to explore whether enhanced somatosensory input through electrical stimulation contributes to improved postural control and functional outcomes. The findings of this study are expected to provide clinically relevant evidence regarding the role of galvanic bath therapy as an adjunctive treatment modality in the rehabilitation of patients with diabetic peripheral neuropathy.

Tipo de estudo

Intervencional

Inscrição (Real)

66

Estágio

  • Não aplicável

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Locais de estudo

      • Ankara, Turquia (Türkiye)
        • Ankara Etlik City Hospital Physical Medicine and Rehabilitation Hospital

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

  • Adulto
  • Adulto mais velho

Aceita Voluntários Saudáveis

Não

Descrição

Inclusion Criteria:

  1. Diagnosis of type 2 diabetes mellitus
  2. Confirmed diagnosis of diabetic distal symmetric polyneuropathy according to the 2009 Toronto Consensus criteria
  3. Age between 40 and 75 years
  4. Adequate cognitive function to understand and respond to questionnaires and follow instructions (Mini-Mental State Examination score ≥ 24)
  5. No initiation or dosage change in neuropathic pain medication within the last 1 month
  6. Sufficient functional mobility to participate in the assessment and treatment protocol (ability to stand independently or with minimal assistance)

Exclusion Criteria:

  1. Presence of lower extremity amputation
  2. Active diabetic foot ulcer, significant skin integrity impairment, or open wound in the treatment area
  3. Cognitive impairment (MMSE < 24) or communication problems interfering with assessments
  4. Presence of orthopedic, musculoskeletal, or peripheral conditions affecting balance
  5. Medical instability
  6. Use of medications affecting balance or cognitive function
  7. Use of assistive devices
  8. Severe musculoskeletal disorders
  9. Initiation or dosage change of neuropathic pain medication within the last 1 month
  10. Presence of Charcot neuroarthropathy
  11. Polyneuropathy due to causes other than diabetes

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Tratamento
  • Alocação: Randomizado
  • Modelo Intervencional: Atribuição Paralela
  • Mascaramento: Solteiro

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Experimental: Four-Cell Galvanic Bath Therapy + Conventional Rehabilitation
Participants received four-cell galvanic bath therapy in addition to a conventional rehabilitation program. The rehabilitation program included range of motion, stretching, strengthening, balance, coordination, and endurance exercises. The intervention was applied for 4 weeks, three sessions per week, with each session lasting approximately one hour.
Four-cell galvanic bath therapy was applied using a direct current (1.5 mA) delivered through water-filled electrodes to both upper and lower extremities for 20 minutes per session, three times per week for 4 weeks.
Outros nomes:
  • Four-Cell Galvanic Bath
  • Galvanic Bath Therapy
A standardized rehabilitation program including range of motion, stretching, strengthening, balance, coordination, and endurance exercises, performed 3 times per week for 4 weeks, with each session lasting approximately 60 minutes.
Comparador Ativo: Conventional Rehabilitation Alone
Participants received a conventional rehabilitation program consisting of range of motion, stretching, strengthening, balance, coordination, and endurance exercises. The program was applied for 4 weeks, three sessions per week, with each session lasting approximately one hour.
A standardized rehabilitation program including range of motion, stretching, strengthening, balance, coordination, and endurance exercises, performed 3 times per week for 4 weeks, with each session lasting approximately 60 minutes.

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Postural Stability (Stability Index) Measured by TecnoBody Prokin PK252
Prazo: Baseline (Week 0), Post-treatment (Week 4), and Follow-up (Week 12)
Postural stability will be assessed using the TecnoBody Prokin PK252 device. The Stability Index parameter reflects postural sway based on center of pressure displacement. Higher values indicate poorer balance performance and reduced postural stability.
Baseline (Week 0), Post-treatment (Week 4), and Follow-up (Week 12)

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Berg Balance Scale (BBS)
Prazo: Baseline (Week 0), Post-treatment (Week 4), and Follow-up (Week 12)
Balance performance will be assessed using the Berg Balance Scale (BBS). The BBS is a 14-item clinical balance assessment scale with a total score ranging from 0 to 56. Higher scores indicate better balance performance and lower fall risk. Assessments will be performed at baseline, post-treatment, and follow-up, and scores will be compared between groups.
Baseline (Week 0), Post-treatment (Week 4), and Follow-up (Week 12)
Functional Reach Test (FRT)
Prazo: Baseline (Week 0), Post-treatment (Week 4), and Follow-up (Week 12)
Dynamic balance will be assessed using the Functional Reach Test (FRT). The maximal forward reach distance will be measured in centimeters while maintaining a fixed standing position without stepping. Greater reach distance indicates better dynamic balance and postural control, whereas shorter reach distance indicates impaired balance performance and increased fall risk. Assessments will be performed at baseline, post-treatment, and follow-up.
Baseline (Week 0), Post-treatment (Week 4), and Follow-up (Week 12)
Timed Up and Go Test (TUG)
Prazo: Baseline (Week 0), Post-treatment (Week 4), and Follow-up (Week 12)
Functional mobility will be assessed using the Timed Up and Go (TUG) test. Participants will stand up from a chair, walk 3 meters, turn around, walk back, and sit down again. Completion time will be recorded in seconds. Shorter completion time indicates better functional mobility and balance performance, whereas longer completion time indicates impaired mobility and balance. Assessments will be performed at baseline, post-treatment, and follow-up.
Baseline (Week 0), Post-treatment (Week 4), and Follow-up (Week 12)
Single Leg Stance Test
Prazo: Baseline (Week 0), Post-treatment (Week 4), and Follow-up (Week 12)
Static balance will be assessed using the Single Leg Stance Test. Participants will be instructed to stand on one leg without external support for as long as possible. Standing duration will be recorded in seconds. Longer standing duration indicates better static balance and postural stability, whereas shorter duration indicates impaired balance performance. Assessments will be performed at baseline, post-treatment, and follow-up.
Baseline (Week 0), Post-treatment (Week 4), and Follow-up (Week 12)
Short-Form McGill Pain Questionnaire (SF-MPQ)
Prazo: Baseline (Week 0), Post-treatment (Week 4), and Follow-up (Week 12)
Pain severity will be assessed using the Short-Form McGill Pain Questionnaire (SF-MPQ). Higher total scores indicate greater pain severity. Assessments will be performed at baseline, post-treatment, and follow-up.
Baseline (Week 0), Post-treatment (Week 4), and Follow-up (Week 12)
Physical Component Summary of SF-12 (PCS-12)
Prazo: Baseline (Week 0), Post-treatment (Week 4), and Follow-up (Week 12)
Physical health status will be assessed using the Physical Component Summary (PCS-12) score of the Short Form-12 Health Survey. Scores range from 0 to 100, with higher scores indicating better physical health status.
Baseline (Week 0), Post-treatment (Week 4), and Follow-up (Week 12)
Mental Component Summary of SF-12 (MCS-12)
Prazo: Baseline (Week 0), Post-treatment (Week 4), and Follow-up (Week 12)
Mental health status will be assessed using the Mental Component Summary (MCS-12) score of the Short Form-12 Health Survey. Scores range from 0 to 100, with higher scores indicating better mental health status.
Baseline (Week 0), Post-treatment (Week 4), and Follow-up (Week 12)

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

24 de dezembro de 2024

Conclusão Primária (Real)

10 de março de 2026

Conclusão do estudo (Real)

10 de março de 2026

Datas de inscrição no estudo

Enviado pela primeira vez

28 de março de 2026

Enviado pela primeira vez que atendeu aos critérios de CQ

10 de maio de 2026

Primeira postagem (Real)

15 de maio de 2026

Atualizações de registro de estudo

Última Atualização Postada (Real)

15 de maio de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

10 de maio de 2026

Última verificação

1 de março de 2026

Mais Informações

Termos relacionados a este estudo

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

NÃO

Descrição do plano IPD

Individual participant data (IPD) will not be shared due to privacy concerns and institutional data protection policies.

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Não

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever